Shkreli's jail-cell business dealings draw scrutiny from the feds: WSJ

prison
Martin Shkreli has reportedly possessed a contraband cell phone in prison. (Pixabay)

Martin Shkreli may have landed himself in more trouble with the law—and bought a longer prison sentence in the process. After the Wall Street Journal reported last week that the "pharma bro” is running a biotech company from prison, federal officials are getting involved.  

The Bureau of Prisons has struck up an investigation, the newspaper reported. And if they find enough evidence to confirm the Journal’s original story, the former Turing Pharmaceuticals CEO could see some time tacked on to his original 7-year sentence. 

Shkreli came to infamy in 2015 after Turing raised the price of a toxoplasmosis drug, Daraprim, by 5,000% overnight. Instead of apologizing, explaining or reversing the hike, Shkreli hit back at critics, quickly gaining fame as the “most hated” man in America.  

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

But it wasn’t the Turing episode that landed Shkreli in prison. He was later charged with fraud relating to his time at another biotech, Retrophin; a jury convicted him in 2017. 

RELATED: Made for TV: Shkreli running his drug company from prison cell, WSJ says 

Fast forward to last week, when the Journal reported that more than a year into his prison sentence, Shkreli still has significant holdings in Turing, which has since changed its name twice to arrive at its current moniker, Phoenixus. And Shkreli is essentially calling shots at that company from behind bars with a contraband cell phone, the WSJ said. 

It didn’t take prison officials long to jump in. They quickly kicked off an investigation, and the violations could add a year onto Shkreli’s sentence, WSJ reported. The FBI is also looking into the issue, according to the Journal.

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.